Bluebird, Celgene myeloma treatment impresses in tiny study


Patients who previously were not helped by repeated treatments for multiple myeloma showed strong benefits from a new type of therapy in a small study, and with no worrisome side effects, drugmaker Bluebird Bio Inc said on Wednesday. The Phase 1 study enrolled patients who had basically run out of options for the blood cancer, after failing on average six previous rounds of treatment, including stem cell transplants.



from Biotech News